share_log

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Price Dropped 5.6% Last Week; Private Companies Would Not Be Happy

浙江ウォルヲーバイオ医薬品株式会社(SZSE:300357)の株価が先週5.6%下落しました。 私企業は幸せではないでしょう。

Simply Wall St ·  03/24 21:58

Key Insights

  • Zhejiang Wolwo Bio-Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • A total of 3 investors have a majority stake in the company with 57% ownership
  • Insiders own 11% of Zhejiang Wolwo Bio-Pharmaceutical

To get a sense of who is truly in control of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are private companies with 39% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

And last week, private companies endured the biggest losses as the stock fell by 5.6%.

In the chart below, we zoom in on the different ownership groups of Zhejiang Wolwo Bio-Pharmaceutical.

ownership-breakdown
SZSE:300357 Ownership Breakdown March 25th 2024

What Does The Institutional Ownership Tell Us About Zhejiang Wolwo Bio-Pharmaceutical?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Zhejiang Wolwo Bio-Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Zhejiang Wolwo Bio-Pharmaceutical's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
SZSE:300357 Earnings and Revenue Growth March 25th 2024

Zhejiang Wolwo Bio-Pharmaceutical is not owned by hedge funds. Zhejiang Wolwo Management Consulting Co., Ltd. is currently the largest shareholder, with 39% of shares outstanding. National Council for Social Security Fund is the second largest shareholder owning 9.8% of common stock, and Gengxi Hu holds about 8.3% of the company stock. Gengxi Hu, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board.

A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 57% stake.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of Zhejiang Wolwo Bio-Pharmaceutical

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our most recent data indicates that insiders own a reasonable proportion of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.. Insiders own CN¥1.4b worth of shares in the CN¥13b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

The general public-- including retail investors -- own 23% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

It seems that Private Companies own 39%, of the Zhejiang Wolwo Bio-Pharmaceutical stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Zhejiang Wolwo Bio-Pharmaceutical has 1 warning sign we think you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする